Last reviewed · How we verify
NCT04785365
Long-Term Follow-Up Study of Patients Receiving ATL001
Phase 2 trial testing Biological: ATL001 in Melanoma in 1 participant. Terminated before completion.
18 October 2023
Quick facts
| Lead sponsor | Achilles Therapeutics UK Limited |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 1 |
| Start date | 1 June 2022 |
| Primary completion | 18 October 2023 |
| Estimated completion | 18 October 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Biological: ATL001
Conditions studied
- Melanoma — all drugs for Melanoma →
- Advanced Non Small Cell Lung Cancer — all drugs for Advanced Non Small Cell Lung Cancer →
Sponsor
Achilles Therapeutics UK Limited — full company profile →
Who can join
18 and older, any sex, with Melanoma or Advanced Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847) or Study ATX-ME-001 (NCT03997474).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
Xie N, Shen G, Huang C, Zhu H. · · 2025 · cited 2× · PMID 40757404 · DOI 10.1097/cm9.0000000000003708
Verify or expand the search:
- PubMed search for NCT04785365
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other Achilles Therapeutics UK Limited trials
Trials by the same sponsor.
- NCT03997474 — ATL001 in Patients With Metastatic or Recurrent Melanoma · Phase 1, PHASE2 · terminated
- NCT04032847 — ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04785365 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Achilles Therapeutics UK Limited
- Last refreshed: 21 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04785365.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing